Edison Investment Research - Acacia Pharma Group PLC (ACPH) Acacia Pharma - Cosmo provides cash injection

Report

Edison Investment Research

Sean Conroy

Acacia Pharma - Cosmo provides cash injection

Acacia Pharma has announced a deal with Cosmo Pharmaceuticals to acquire the US rights to sedative ByFavo (remimazolam). This is a multi-faceted deal â€“ the addition of ByFavo broadens Acaciaâ€™s US commercial pipeline beyond key asset BARHEMSYS (post-operative nausea and vomiting (PONV)). Both assets are under FDA review, with imminent PDUFA dates (BARHEMSYS 26 February, ByFavo 5 April) and potential US launch during H220. Critically, Cosmoâ€™s equity investment of â‚¬10m plus access to loan facilities (up to $35m) for Acacia bridges its short-term funding gap, enabling it to expand its much-needed US commercial infrastructure to support both product launches. Management changes continue; as CFO Christine Soden is set to retire, the board has appointed Gary Gemignani as successor. We value Acacia at â‚¬882m or â‚¬13.8/share.

21/01/2020 7 EN

Underlying

Acacia Pharma Group PLC

Acacia Pharma Group Plc. Acacia Pharma Group PLC is a United Kingdom-based company specialized in the pharmaceutical industry. The pharmaceutical group focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients. Its pipeline includes BAREMIS, an intravenous formulation of amisulpride, which is a selective dopamine antagonist that has completed phase 3 clinical development for the prophylaxis and treatment of Postoperative nausea and vomiting (PONV), and APD403, which is based on the selective dopamine antagonist amisulpride and it is being developed as an intravenous injection for cancer patients to be administered immediately before chemotherapy to prevent acute chemotherapy-induced nausea & vomiting ( CINV).

See profile

GB00BYWF9Y76 Euronext Brussels United Kingdom

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

GlobeNewsWire

Scheme of arrangement becoming effective

Scheme of arrangement becoming effective Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 9 June 2022, 1.00 p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under Part 26 of the Companies Act 2006 Scheme becomi...

June 9, 2022 June 9, 2022 1 EN

GlobeNewsWire

Court Sanction of the Scheme of Arrangement

Court Sanction of the Scheme of Arrangement Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 7 June 2022, [1.00] p.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected by means of a scheme of arrangement under ...

June 7, 2022 June 7, 2022 1 EN

GlobeNewsWire

Acacia Pharma Results of the Court Meeting and the General Meeting held on 19 May 2022

Acacia Pharma Results of the Court Meeting and the General Meeting held on 19 May 2022 Acacia Pharma Group PLC THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AND REGULATED INFORMATION NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 20 May 2022, 8:00 a.m. (Brussels time) RECOMMENDED ACQUISITION of ACACIA PHARMA GROUP PLC by EAGLE PHARMACEUTICALS, INC. to be effected b...

May 20, 2022 May 20, 2022 1 EN

International Public Partnerships - Consistently and responsibly delivering

International Public Partnerships’ (INPP’s) FY23 results show that it continues to deliver consistent and predictable returns for investors, while delivering environmental and social benefits for the individuals and communities that are served by its assets. Despite this strong performance and a substantial need for private infrastructure funding, the macroeconomic environment has weighed on INPP’s share price, in common with the wider sector. Regardless, attractive returns are available from the existing portfolio with opportunities for further enhancement.

15h / 28m 15h / 28m 1 EN

Kate Heseltine

Kate Heseltine

Portobello SpA - Focus back on the operations

Portobello’s FY23 results demonstrate the primary effects of the out-of-court settlement with respect to VAT and direct taxes (a higher year-end net debt position) and the secondary effects, such as disruption to its trading activities due to management’s focus on cash generation and the company’s inability to trade as previously expected. Following the period end, two capital raises totalling €12.6m, including €3.8m by three of the executive management team, from a maximum mandated amount of €20m, have improved the company’s financial position. The requirement to improve the balance sheet fur...

16h / 11m 16h / 11m 1 EN

Kate Heseltine

Kate Heseltine

Intralot - Focus on business development in FY24

Intralot enjoyed good underlying trends in performance in FY23 with encouraging trends in its main countries of focus and further progress on profitability. The much-improved balance sheet and extension of debt maturities mean management can focus on the significant business development opportunities available in FY24 and beyond. The share price looks attractive in the absence of potential new contract wins, which could be materially enhancing to the valuation.

21h / 26m 21h / 26m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Acacia Pharma - Cosmo provides cash injection

Scheme of arrangement becoming effective

Court Sanction of the Scheme of Arrangement

Acacia Pharma Results of the Court Meeting and the General Meeting held on 19 May 2022

International Public Partnerships - Consistently and responsibly delivering

Portobello SpA - Focus back on the operations

Intralot - Focus on business development in FY24

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe